Prospective Descriptive Study of Injuries Associated to Anterior Shoulder Dislocations in Patients Over 40 Years

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorCorporacion Parc Tauli

About this trial

The glenohumeral joint has the highest rate of dislocation of the whole body, due to its high mobility and the special characteristics of its anatomy. It is estimated that every year between 1-2% of the population will suffer from glenohumeral dislocation. The vast majority of studies are based on young patients under the age of 40, given that at this age they have the higher incidence and at the same time, they have higher redislocation index. However, the investigators are in front of a more active population with a longer life expectancy. That is why the cases of anterior glenohumeral dislocations are increasing in people older than 40 years. Given that most studies focus on younger patients, the investigators lack knowledge about which injuries are associated with dislocation at this age and whether these influence its clinical evolution.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

More than 40 years old

First episode of traumatic anterior gelnohumeral dislocation seen in Rx

Acceptance to be checked over 2 years

Acceptance to be submitted to TAC, NMR, EMG and Bilateral Ultrasound

Disqualifiers

Previous fractures in this extremity

Previous neurovascular lesions in this extremity

Other associated lesions

Cognitive alterations or dementia which prevent completing the protocols. Patients with <14 points in Mini-mental test.

Trial population

All consecutive patients with an anterior glenohumeral dislocation and over 40 years old who came to the Emergency Room in the Hospital between June 2023 and June 2025

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Reduction

    Procedure/Surgery

    An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.

Treatment groups

120 Participants
are divided into 1 treatment group
Group A: Humeral anterior dislocation1 intervention

Trial outcomes

Primary outcomes

1

Characterization of associated lesions

Time frame
At the three months visit including assessment of NMR/EMG/TAC/Bilateral Ultrasound

Secondary outcomes

1

Constant Functional Test

Time frame
3, 6, 12 and 24 months
2

WOSI test

Time frame
3, 6, 12 and 24 months
3

SST

Time frame
3, 6, 12 and 24 months
4

Redislocations

Time frame
3, 6, 12 and 24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.